cas 56341-41-4|| where to buy 5-Fluorooxindole

Nom du produit:5-Fluorooxindole

IUPAC Name:5-fluoro-2,3-dihydro-1H-indol-2-one

Unité d'emballage	Stock disponible	Prix($)
CM148054-100g	in stock	ƙǧƻ
CM148054-500g	in stock	Ȧǧſ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 56341-41-4 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:56341-41-4; Formule moléculaire:C8H6FNO; Point de fusion:-; Code SMILES:C1=C2C(=CC=C1F)NC(=O)C2; Densité:

: Numéro de catalogue:CM148054; Poids moléculaire:151.14; Point d'ébullition:307.2°C at 760 mmHg; N° Mdl:MFCD02179598; Stockage:Keep in a tight container and store at ambient temperature

: Indolinones; Indolinone derivatives have in common the presence of a hydrogen bond between the C-2 carbonyl and a hydrogen donor in a side chain, generally a pyrrole ring. Indolinone displays very promising antitumor properties by inhibiting various kinase families.

: Vorolanib; EyePoint Pharmaceuticals announced on December 4th announced positive topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert E™. Vorolanib brings a new mechanistic approach to the treatment of VEGF-mediated retinal diseases as a pan-VEGF receptor blocker, blocking all VEGF isoforms. Vorolanib features reduced off-target binding and at clinically relevant doses does not inhibit Tie-2, a critical pathway associated with vascular stability, which may result in an improved efficacy. Further, in an in-vivo model of retinal detachment, vorolanib demonstrated neuroprotection, and potential antifibrotic benefits.